Şeyma Eroğlu

Dr. Şeyma Eroğlu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSüleyman Can
Süleyman Can
VÇVeli Çakıcı
Veli Çakıcı
GKGizem bakır kahveci
Gizem bakır kahveci
ŞEŞeyma Eroğlu
Şeyma Eroğlu
BTBurak Tok
Burak Tok
IGivo gokmen
ivo gokmen
Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti-vascular endothelial growth factor (VEGF)-based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusions: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF-based strategies, warranting prospective validation.

20 August 2025 in Spor ve Performans Araştırmaları Dergisi
Verified
Journal Article
Open access
PDF file
BUBüşra Umay
Büşra Umay
ŞEŞeyma Eroğlu
Şeyma Eroğlu
BTBurak Tok
Burak Tok
HKHürmüz Koç
Hürmüz Koç
This study was conducted to determine the effects of calisthenic exercises on certain physical parameters and muscle strength in women who have undergone mastectomy surgery. A total of 30 women, aged between 40 and 60 years, who were receiving post-mastectomy treatment at Çanakkale Onsekiz Mart University Training and Research Hospital, voluntarily participated in the study. Participants were selected using a simple random sampling method. Individuals deemed eligible for measurements by a specialist oncologist were included in the study. Institutional permission and ethical approval were obtained from the Faculty of Medicine at Çanakkale Onsekiz Mart University. The participants’ ages were determined based on official identification. Measurements included height, body weight, body fat percentage, circumference measurements, handgrip strength, leg and back strength. The results were presented as arithmetic means (x̄) and standard deviations (sd). Independent samples t-test was used to determine differences between groups. The level of significance was set at p

11 February 2026 in Archives of Dermatological Research
Verified
Journal Article
Closed access
CACemre Aydeğer
Cemre Aydeğer
DADAMLA AYKORA
DAMLA AYKORA
ŞEŞeyma Eroğlu
Şeyma Eroğlu
MMMustafa Makav
Mustafa Makav
BYBaşak Yavuz
Başak Yavuz
HEHüseyin Avni Eroğlu
Hüseyin Avni Eroğlu

31 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SCSüleyman Can
Süleyman Can
VÇVeli Çakıcı
Veli Çakıcı
GKGizem bakır kahveci
Gizem bakır kahveci
ŞEŞeyma Eroğlu
Şeyma Eroğlu
BTBurak Tok
Burak Tok
IGivo gokmen
ivo gokmen
Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti–vascular endothelial growth factor (VEGF)–based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusion: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF–based strategies, warranting prospective validation.

30 January 2026 in Medical Science and Discovery
Verified
Journal Article
Open access
PDF file
IGivo gokmen
ivo gokmen
ŞEŞeyma Eroğlu
Şeyma Eroğlu
Dear Author The incorporation of immune checkpoint inhibitors into neoadjuvant and adjuvant treatment strategies for early-stage solid tumors has prompted a critical reassessment of how treatment response should be interpreted and translated into long-term therapeutic decisions. Data from contemporary neoadjuvant immunotherapy trials across multiple tumor types have revealed a recurring and biologically intriguing pattern: patients achieving deep pathologic responses may experience durable clinical benefit despite limited or even absent adjuvant immune checkpoint inhibition, whereas patients with residual disease appear to derive disproportionate benefit from continued postoperative therapy. This divergence—observed in KEYNOTE-522 in early-stage triple-negative breast cancer, CheckMate 816 in resectable non–small-cell lung cancer, response-adapted melanoma studies such as PRADO and NADINA, and short-course neoadjuvant immunotherapy in mismatch repair–deficient colon cancer (NICHE-2)—suggests that mechanisms beyond treatment intensity alone are operative and challenges the implicit assumption that immunotherapy benefit follows a linear “dose–duration–benefit” paradigm (1–6). The immune system is inherently adaptive; however, immune learning does not progress in a strictly linear or indefinitely amplifiable manner. Once critical thresholds of antigen recognition, effector T-cell activation, and immune memory formation are achieved, additional immune stimulation may yield diminishing marginal returns. This biologic ceiling effect provides a plausible explanation for the limited incremental benefit of continued adjuvant immunotherapy in patients who have already achieved a pathologic complete response (pCR). In such cases, treatment continuation may primarily serve to preserve an already established immune equilibrium rather than generate further clinically meaningful immune education (7). Importantly, the efficiency and durability of this immune learning process likely vary across tumor types and individual patients, influenced by baseline tumor immunogenicity, tumor mutational burden, and immune contexture, including PD-L1 expression. In contrast, patients with residual disease but without clear evidence of immune escape may represent a distinct and potentially modifiable biologic state. In these individuals, neoadjuvant therapy may have successfully primed antitumor immunity without surpassing the threshold required for complete tumor eradication. Following surgical debulking, the persistence of minimal residual disease and continued antigen exposure may allow adjuvant immunotherapy to stabilize this partially trained immune response and suppress micrometastatic progression. Accordingly, the observed benefit in patients with residual disease may reflect not greater therapeutic potency, but rather the continued presence of a biologically relevant immune target (8). These considerations raise important questions regarding the adequacy of pCR as a standalone biomarker for predicting immunotherapy benefit. While surgical pathology effectively captures local tumor eradication, the principal contribution of immunotherapy likely lies in the establishment of durable, systemic immune surveillance. Consequently, pCR—although a robust surrogate for chemotherapy sensitivity—may incompletely capture the long-term clinical impact of immune-based therapies (9). The integration of additional biomarkers reflecting systemic immune activation, such as circulating tumor DNA clearance or markers of immune memory, may therefore be necessary to more accurately define the threshold of effective immune learning. In summary, although the efficacy of immunotherapy in early-stage disease is well established, increasing attention should be directed toward defining treatment duration according to biological necessity rather than maximal exposure, as schematically illustrated in Figure 1. Recognizing the nonlinear nature of immune learning supports the development of more refined treatment strategies that integrate pathologic response, residual disease biology, and markers of immune memory. Future clinical trials should be explicitly designed to test response-adapted and biomarker-driven de-escalation strategies, including randomized studies in which patients achieving pCR or deep molecular response are assigned to abbreviated or omitted adjuvant immunotherapy. Such approaches may represent a critical step toward more rational, personalized, and toxicity-conscious treatment paradigms (10).